ATE510840T1 - Kondensierte thiazol-derivate als kinasehemmer - Google Patents
Kondensierte thiazol-derivate als kinasehemmerInfo
- Publication number
- ATE510840T1 ATE510840T1 AT07733382T AT07733382T ATE510840T1 AT E510840 T1 ATE510840 T1 AT E510840T1 AT 07733382 T AT07733382 T AT 07733382T AT 07733382 T AT07733382 T AT 07733382T AT E510840 T1 ATE510840 T1 AT E510840T1
- Authority
- AT
- Austria
- Prior art keywords
- kinase inhibitors
- thiazole derivatives
- condensed thiazole
- condensed
- substituted
- Prior art date
Links
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- 150000007979 thiazole derivatives Chemical class 0.000 title 1
- QGUSXKFSPVAZOB-UHFFFAOYSA-N 6,7-dihydro-5h-[1,3]thiazolo[5,4-c]pyridin-4-one Chemical class O=C1NCCC2=C1SC=N2 QGUSXKFSPVAZOB-UHFFFAOYSA-N 0.000 abstract 1
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 abstract 1
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 abstract 1
- 229940124639 Selective inhibitor Drugs 0.000 abstract 1
- 230000001363 autoimmune Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 230000002503 metabolic effect Effects 0.000 abstract 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 abstract 1
- 230000000626 neurodegenerative effect Effects 0.000 abstract 1
- 230000003040 nociceptive effect Effects 0.000 abstract 1
- 230000000771 oncological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0612644A GB0612644D0 (en) | 2006-06-26 | 2006-06-26 | Therapeutic agents |
| GB0620062A GB0620062D0 (en) | 2006-10-10 | 2006-10-10 | Therapeutic agents |
| PCT/GB2007/002390 WO2008001076A1 (en) | 2006-06-26 | 2007-06-26 | Fused thiazole derivatives as kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE510840T1 true ATE510840T1 (de) | 2011-06-15 |
Family
ID=38671000
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT07733382T ATE510840T1 (de) | 2006-06-26 | 2007-06-26 | Kondensierte thiazol-derivate als kinasehemmer |
Country Status (20)
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009071890A1 (en) * | 2007-12-04 | 2009-06-11 | Ucb Pharma S.A. | Tricyclic kinase inhibitors |
| WO2009071895A1 (en) * | 2007-12-04 | 2009-06-11 | Ucb Pharma S.A. | Fused thiazole and thiophene derivatives as kinase inhibitors |
| AU2008343932B2 (en) | 2007-12-19 | 2013-08-15 | Amgen Inc. | Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors |
| ATE531372T1 (de) | 2008-04-07 | 2011-11-15 | Amgen Inc | Gem-disubstituierte und spirocyclische aminopyridine/pyrimidine als zellcyclus- inhibitoren |
| JPWO2009130900A1 (ja) * | 2008-04-24 | 2011-08-11 | 日本曹達株式会社 | オキシム誘導体、中間体化合物および植物病害防除剤 |
| US8603945B2 (en) * | 2008-07-23 | 2013-12-10 | The Regents Of The University Of California | Methods and compositions for providing salicyclic acid-independent pathogen resistance in plants |
| EP2341052A4 (en) * | 2008-09-05 | 2011-10-12 | Shionogi & Co | RING-CONDENSED MORPHOLINE DERIVATIVITY WITH PI3K-INHIBITING EFFECT |
| AU2010216219A1 (en) | 2009-02-17 | 2011-09-01 | Vertex Pharmaceuticals Incorporated | Tetrahydrothiazolopyridine inhibitors of phosphatidylinositol 3-kinase |
| AR076126A1 (es) * | 2009-03-18 | 2011-05-18 | Schering Corp | Compuestos biciclicos como inhibidores de diacilglicerol aciltransferasa |
| UY32582A (es) * | 2009-04-28 | 2010-11-30 | Amgen Inc | Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero |
| ES2638323T3 (es) * | 2009-05-20 | 2017-10-19 | Glaxosmithkline Llc | Derivados de tiazolopirimidinona como inhibidores de PI3 quinasa |
| GB0912946D0 (en) | 2009-07-24 | 2009-09-02 | Addex Pharmaceuticals Sa | New compounds 5 |
| MX2012002059A (es) | 2009-08-20 | 2012-04-19 | Karus Therapeutics Ltd | Compestos heterociclicos triciclicos como inhibidores de fosfoionositida 3-quinasa. |
| EA020010B1 (ru) * | 2009-12-18 | 2014-07-30 | Янссен Фармацевтика Нв | БИЦИКЛИЧЕСКИЕ ТИАЗОЛЫ В КАЧЕСТВЕ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ mGluR5 РЕЦЕПТОРОВ |
| ES2431302T3 (es) | 2009-12-18 | 2013-11-25 | Janssen Pharmaceutica, N.V. | Tiazoles bicíclicos como moduladores alostéricos de receptores mGluR5 |
| EP2582693B1 (de) | 2010-06-15 | 2016-03-30 | Bayer Intellectual Property GmbH | Neue ortho-substituierte arylamid-derivate |
| BR112013007056A2 (pt) | 2010-10-01 | 2019-09-24 | Basf Se | compostos de imina |
| AU2011316016A1 (en) * | 2010-10-13 | 2013-05-30 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
| BR112013012961A2 (pt) * | 2010-11-24 | 2019-09-24 | Exelixis Inc | benzoxazepinas como inhibidores de mtor e métodos de seu uso e fabricação |
| CN102649777B (zh) * | 2011-02-25 | 2014-03-12 | 中国中化股份有限公司 | 一种制备1-芳基-3-羧基-5-吡唑啉酮类化合物的方法 |
| WO2012129344A1 (en) | 2011-03-23 | 2012-09-27 | Amgen Inc. | Fused tricyclic dual inhibitors of cdk 4/6 and flt3 |
| JO3398B1 (ar) | 2011-12-22 | 2019-10-20 | Novartis Ag | مشتقات 2،3- ثانى هيدرو- بنزو[1,4] أوكسازين والمركبات المتعلقة بها كمثبطات كيناز فسفواينوسيتيد-3 (pi3k) لمعالجة على سبيل المثال التهاب المفاصل الروماتيدي |
| US9447079B2 (en) | 2013-03-14 | 2016-09-20 | Epizyme, Inc. | PRMT1 inhibitors and uses thereof |
| US9023883B2 (en) | 2013-03-14 | 2015-05-05 | Epizyme, Inc. | PRMT1 inhibitors and uses thereof |
| US9120757B2 (en) | 2013-03-14 | 2015-09-01 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
| US9133189B2 (en) | 2013-03-14 | 2015-09-15 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
| US20160039767A1 (en) | 2013-03-14 | 2016-02-11 | Epizyme, Inc. | Pyrazole derivatives as prmt1 inhibitors and uses thereof |
| US9365527B2 (en) | 2013-03-14 | 2016-06-14 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
| WO2014153208A1 (en) | 2013-03-14 | 2014-09-25 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
| EP2970220A2 (en) | 2013-03-14 | 2016-01-20 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
| BR112015022785A2 (pt) | 2013-03-14 | 2017-07-18 | Epizyme Inc | composto; composição farmacêutica; kit ou artigo farmacêutico embalado; método de inibição de uma arginina metil transferase (rmt); método de modulação da expressão genética; método de modulação da transcrição; e método de tratamento de um distúrbio mediado por rmt |
| CA2903264A1 (en) | 2013-03-14 | 2014-11-06 | Epizyme, Inc. | Pyrazole derivatives as arginine methyltransferase inhibitors and uses thereof |
| WO2015059049A1 (de) * | 2013-10-21 | 2015-04-30 | Umicore Ag & Co. Kg | Monoarylierung aromatischer amine |
| GB201402431D0 (en) | 2014-02-12 | 2014-03-26 | Karus Therapeutics Ltd | Compounds |
| GB201514760D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compounds and method of use |
| GB201514758D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Formulation |
| GB201514754D0 (en) * | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compounds |
| US10722484B2 (en) | 2016-03-09 | 2020-07-28 | K-Gen, Inc. | Methods of cancer treatment |
| CN108570043A (zh) * | 2018-06-20 | 2018-09-25 | 王延娇 | 一种化合物及其作为选择性pi3k抑制剂在治疗肿瘤中的应用 |
| US20220202824A1 (en) | 2018-09-13 | 2022-06-30 | Stemline Therapeutics, Inc. | Methods for Treating Centronuclear Myopathy |
| AU2019410261B2 (en) | 2018-12-19 | 2025-10-02 | Leo Pharma A/S | Amino-acid anilides as small molecule modulators of IL-17 |
| BR112021013105A2 (pt) * | 2019-01-08 | 2021-09-21 | Kyorin Pharmaceutical Co., Ltd. | Inibidor de 15-pgdh |
| JP7532385B2 (ja) | 2019-01-31 | 2024-08-13 | 杏林製薬株式会社 | １５－ｐｇｄｈ阻害薬 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0508471D0 (en) | 2005-04-26 | 2005-06-01 | Celltech R&D Ltd | Therapeutic agents |
-
2007
- 2007-06-26 WO PCT/GB2007/002390 patent/WO2008001076A1/en not_active Ceased
- 2007-06-26 EP EP07733382A patent/EP2035436B1/en active Active
- 2007-06-26 US US12/306,151 patent/US8242116B2/en active Active
- 2007-06-26 AT AT07733382T patent/ATE510840T1/de not_active IP Right Cessation
- 2007-06-26 ES ES07733382T patent/ES2365258T3/es active Active
-
2008
- 2008-06-24 PL PL08775774T patent/PL2170906T3/pl unknown
- 2008-06-24 AU AU2008269577A patent/AU2008269577B2/en not_active Ceased
- 2008-06-24 PT PT87757746T patent/PT2170906E/pt unknown
- 2008-06-24 MY MYPI20095404A patent/MY148852A/en unknown
- 2008-06-24 RS RSP20130257 patent/RS52824B/sr unknown
- 2008-06-24 DK DK08775774.6T patent/DK2170906T3/da active
- 2008-06-24 MX MX2009013740A patent/MX2009013740A/es active IP Right Grant
- 2008-06-24 ES ES08775774T patent/ES2416364T3/es active Active
- 2008-06-24 CN CN200880024430XA patent/CN101687885B/zh active Active
- 2008-06-24 EA EA201000038A patent/EA017187B1/ru not_active IP Right Cessation
- 2008-06-24 EP EP08775774A patent/EP2170906B1/en active Active
- 2008-06-24 US US12/666,481 patent/US8338592B2/en active Active
- 2008-06-24 CA CA2692085A patent/CA2692085C/en active Active
- 2008-06-24 ME MEP-2013-70A patent/ME01592B/me unknown
- 2008-06-24 HR HRP20130523AT patent/HRP20130523T1/hr unknown
-
2009
- 2009-12-10 IL IL202659A patent/IL202659A0/en active IP Right Grant
- 2009-12-31 CO CO09149835A patent/CO6270229A2/es active IP Right Grant
-
2012
- 2012-11-20 US US13/681,840 patent/US8710054B2/en active Active
-
2013
- 2013-07-03 CY CY20131100552T patent/CY1114419T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2008269577B2 (en) | 2012-12-20 |
| CO6270229A2 (es) | 2011-04-20 |
| EA201000038A1 (ru) | 2010-06-30 |
| US8338592B2 (en) | 2012-12-25 |
| AU2008269577A1 (en) | 2008-12-31 |
| MY148852A (en) | 2013-06-14 |
| ME01592B (me) | 2014-09-20 |
| ES2416364T3 (es) | 2013-07-31 |
| EP2170906B1 (en) | 2013-04-03 |
| US20130079330A1 (en) | 2013-03-28 |
| PL2170906T3 (pl) | 2013-08-30 |
| US8710054B2 (en) | 2014-04-29 |
| EA017187B1 (ru) | 2012-10-30 |
| EP2035436A1 (en) | 2009-03-18 |
| IL202659A0 (en) | 2010-06-30 |
| CA2692085A1 (en) | 2008-12-31 |
| ES2365258T3 (es) | 2011-09-27 |
| EP2035436B1 (en) | 2011-05-25 |
| CN101687885A (zh) | 2010-03-31 |
| PT2170906E (pt) | 2013-06-25 |
| US8242116B2 (en) | 2012-08-14 |
| US20110003785A1 (en) | 2011-01-06 |
| CA2692085C (en) | 2015-10-13 |
| DK2170906T3 (da) | 2013-06-24 |
| HRP20130523T1 (en) | 2013-07-31 |
| MX2009013740A (es) | 2010-02-01 |
| EP2170906A1 (en) | 2010-04-07 |
| CY1114419T1 (el) | 2016-08-31 |
| US20100137302A1 (en) | 2010-06-03 |
| RS52824B (cg-RX-API-DMAC10.html) | 2013-10-31 |
| CN101687885B (zh) | 2012-08-22 |
| WO2008001076A1 (en) | 2008-01-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE510840T1 (de) | Kondensierte thiazol-derivate als kinasehemmer | |
| ATE526021T1 (de) | Kondensierte thiazol-derivate als kinase-hemmer | |
| MY146387A (en) | Thieno-pyridine derivatives as mek inhibitors | |
| WO2009081105A3 (en) | Quinoxaline and quinoline derivatives as kinase inhibitors | |
| SMT201600089B (it) | Composti di 3,4-diidropirazino[2,3-b]pirazin-2(1 h)-one come inibitori di chinasi mtor per indicazioni oncologiche e malattie associate al percorso mtor/p13k/akt | |
| NO20081133L (no) | Tieno[2,3-B]-pyridin-5-karbonitriler som protein kinase inhibitorer | |
| WO2008020206A3 (en) | Fused thiophene derivatives as mek inhibitors | |
| WO2010052448A3 (en) | Fused pyrazine derivatives as kinase inhibitors | |
| CL2008003280A1 (es) | Compuestos derivados de 1h-pirazolo[3,4-b]piridina)-4-aril sustituidas; la composicion farmaceutica que los contiene; y sus procesos de preparacion. | |
| PL2395004T3 (pl) | Pochodne pirolo[2,3-b]pirydyny jako inhibitory kinazy białkowej | |
| EP3542629A3 (en) | Dithiol compounds, derivatives, and uses therefor | |
| NO20092657L (no) | Bicyclic heterocyclic compounds as FGFR inhibitors | |
| HUE036953T2 (hu) | 2,3-dihidro-benzo[1,4]oxazin-származékok és rokon vegyületek, mint foszfoinozitid-3-kináz (PI3K) inhibitorok például reumatoid arthritis kezelésére | |
| CO6220934A2 (es) | Derivados de imidazolidinacaboxamida como inhibidores de lipasas y foffolipasas | |
| NO20060279L (no) | Thienopyridonderivater som kinaseinhibitorer | |
| DK1991541T3 (da) | Nye pyron-indolderivater samt fremgangsmåde til deres fremstilling | |
| DK2124944T3 (da) | Pyrazolo[3,4-b]pyridinderivater som phosphodiesteraseinhibitorer | |
| WO2006098961A3 (en) | Fused thieno [2, 3-b] pyridine and thiazolo [5, 4-b] pyridine compounds for inhibiting ksp kinesin activity | |
| UA99469C2 (ru) | Конденсированные производные тиазола как ингибиторы киназы | |
| EP3851439A4 (en) | Furo[3,4-b]pyrrole-containing btk inhibitor | |
| HUE066411T2 (hu) | Izotiazolo[5,4-d]pirimidin vegyület mint IRAK4 inhibitor | |
| EP2490693A4 (en) | Pyrazolo [3,4-B] PYRIDINE-4-ON-KINASE INHIBITORS | |
| DOP2009000289A (es) | Derivados de tiazol fusionados como inhibidores de quinasa | |
| NO20090269L (no) | Fenolpentadienoylderivater og deres anvendelse som PAR-1-antagonister | |
| DK1784403T3 (da) | Pyrrolo[3,2-b]pyridinderivater samt fremgangsmåder til deres fremstilling |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |